Nucleoside Analogs in Cancer Therapy

Nucleoside Analogs: Cellular Pharmacology, Mechanisms of Action, and Strategies for Combination Therapy, William Plunkett and Varsha Gandhi
Induction of Apoptosis by Nucleoside Analogs, Peng Huang and Susan Wright
Pharmacokinetics of Purine Nucleoside Analogs, Jan Liliemark and Gunnar Juliusson
Clinical Development of 2'-Deoxycoformycin, Bruce D. Cheson and Michael R. Grever
Clinical Development of Fludarabine, Axel-R. Hanauske and Daniel D. Von Hoff
Development of 2-Chlorodeoxyadenosine (2-CdA) as a Chemotherapeutic and Immunosuppressive Drug, Ernest Beutler, Dennis Carson, Robert McMillan, and Robert Longmire
Defining the Optimal Dose Schedule of Purine Analogs and Assessment of Response, Jorge E. Cortes and Susan M. O'Brien
Clinical Trials of the Purine Analogs in Chronic Lymphocytic Leukemia, Michael J. Keating
Treatment of Hairy Cell Leukemia with Nucleoside Analogs, Alan Saven and Lawrence D. Piro
Clinical Trials with Nucleoside Analogs in Lymphomas, Wolfgang Hiddemann and Christiane Pott-Hoeck
Clinical Trials with Nucleoside Analogs in Other Hematologic Malignancies, Jorge E. Cortes, Hagop Kantarjian, Susan M. O'Brien, and Michael J. Keating
Nucleoside Analogs as Radiosensitizing Agents, Vincent Grégoire and Walter N. Hittelman
2-Chlorodeoxyadenosine in Nonmalignant Disorders, Ernest Beutler, Dennis Carson, J. C. Sipe, J. S. Romine, Robert McMillan, Z. M. Younossi, V. D. Rodgers, James A. Koziol, and J. Zyroff
Fludarabine in Nonmalignant Disorders, Ioannis O. Tassiulas, John C. Davis, Jr., Barri J. Fessler, Nobuaki Hama, Thomas A. Fleisher, Howard A. Austin III, and Dimitrios T. Boumpas
Toxicities Associated with Purine Analog Therapy, Bruce D. Cheson